Karyopharm Therapeutics Competitors and Similar CompaniesClear all
Karyopharm Therapeutics's competitors and similar companies include Halozyme Therapeutics, Apeloa Pharmaceutical, Faes Farma and STADA.
 Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company that pioneers in cancer therapies. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Apeloa Pharmaceutical Apeloa Pharmaceutical (普洛药业股份有限公司) is a company that develops and produces pharmaceutical products. |  Faes Farma Faes Farma is a pharmaceutical company that develops, produces and commercializes pharmaceutical products and raw materials. | ||
Founding Date | Founding Date 2008 | Founding Date 1998 | Founding Date 1989 | Founding Date 1933 | Founding Date 1895 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Newton, US HQ Givatayim, IL | Locations San Diego, US HQ | Locations CN HQ | Locations Leioa, ES HQ Madrid, ES Atlanta, US | Locations Bad Vilbel, DE HQ Beijing, CN Hangzhou Shi, CN Shanghai, CN Bad Vilbel, DE Budapest, HU Vilnius, LT see more |
Employees | Employees 22818% decrease | Employees 373157% increase | Employees 7,060 | Employees 1,775 | Employees 12,33911% increase |
Valuation ($) | Valuation ($) 111.7 m | Valuation ($) 6.4 b | Valuation ($) 2.7 b | Valuation ($) 1.2 b | Valuation ($) 6 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $146.1m (FY, 2025) | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) ¥9.7b (FY, 2025) | Revenue (est.) €493.6m (FY, 2024) | Revenue (est.) €3b (FY, 2020) |
Cost of goods | Cost of goods $5.9m (FY, 2025) | Cost of goods $228.8m (FY, 2025) | Cost of goods ¥7.2b (FY, 2025) | Cost of goods €167.1m (FY, 2024) | Cost of goods €1.3b (FY, 2020) |
Gross profit | Gross profit $140.1m (FY, 2025) | Gross profit $1.2b (FY, 2025) | Gross profit ¥2.5b (FY, 2025) | Gross profit €342.9m (FY, 2024) | Gross profit €1.7b (FY, 2020) |
Net income | Net income ($196m) (FY, 2025) | Net income $316.9m (FY, 2025) | Net income ¥890.7m (FY, 2025) | Net income €111.1m (FY, 2024) | Net income €181.9m (FY, 2020) |
Operating ⚠ | |||||
Patents (US) | Patents (US) N/A | Patents (US) 43 (FY, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) 2 (Nov, 2020) |
Funding | |||||
Total funding raised | Total funding raised $ 248.7m | Total funding raised $ 171.9m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Halozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyApeloa Pharmaceutical
HQ
CN
Employees
7,060
Apeloa Pharmaceutical (普洛药业股份有限公司) is a company that develops and produces pharmaceutical products.
View companyFaes Farma
HQ
Leioa, ES
Employees
1,775
Faes Farma is a pharmaceutical company that develops, produces and commercializes pharmaceutical products and raw materials.
View company
STADA
HQ
Bad Vilbel, DE
Employees
12,339↑ 11% increase
STADA Arzneimittel is a company engaged in the healthcare and pharmaceuticals business.
View company